Molecular Partners Announces Q3 2026 Financial Results and Strategic Focus on Radiopharmaceuticals

Molecular Partners reported unaudited third-quarter 2026 results and announced it will focus exclusively on developing radiopharmaceuticals. The company is streamlining resources, with the changes expected to be fully implemented by Q2 2027 and cost reductions taking effect in the second half of 2027. It reaffirmed its clinical development timelines and highlighted progress on MP0712, a Radio-DARPin candidate co-developed with Orano Med for small cell lung cancer and other neuroendocrine cancers. The article did not provide financial figures or report a stock-price movement.